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There was an error in the second sentence of the legend for Figure
2. The correct sentence is as follows:
The pathway of the tip of the re-entrant wave front circled in a
counterclockwise direction (A to E) around the insertion site
of a large pectinate muscle to the underlying atrial tissue (see
Fig. 1B).
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The affiliation for Dr. Nagara Tamaki was incorrectly listed. Dr.
Tamaki belongs to the Department of Nuclear Medicine, Hok-
kaido University, School of Medicine, Sapporo, Japan. The correct
affiliation is: Nagara Tamaki, MD†.
The second sentence of the Results section of the Abstract was
incorrect. The correct sentence is: Of 24 patients without coronary
stenosis or spasm, 22 showed normal BMIPP SPECT (speci-
ficity  92%) and 23 showed normal tetrofosmin SPECT
(specificity  96%).
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The authors have noted an error in Table 2 and Figure 1. The
major implication is that reduction of nonfatal stroke associated
with CCB use for hypertension does not outweigh but almost
exactly balances the increase in MI. Corrected data show a relative
risk for nonfatal stroke of 0.842 (p  0.013). The relative risk for
nonfatal MI remains 1.17 (p  0.036). Respective Bonferroni-
corrected p values for nonfatal stroke and nonfatal MI are 0.052
and 0.144. In addition, in type 2 diabetics, CCBs increased major
cardiovascular events with relative risk not of 1.258 but of 1.339
(confidence intervals 1.074 to 1.670, p  0.010), thereby more
strongly supporting the provisional hypothesis that CCBs may
be less safe than ACE inhibitors in diabetics. The revised Table
2 and Figure 1 are printed here. The authors apologize for the
error.
Table 6. Final Multiple Logistic Regression Model Predicting Six-Month Mortality in Patients
Who Survived  10 Days After CABG
Characteristics Odds Ratio 95% CI p Value
Ejection fraction (35% vs. 35%) 2.93 1.65–5.22 0.001
Congestive heart failure 2.14 1.23–3.74 0.01
Peripheral vascular disease 2.25 1.35–3.75 0.01
Cardiac arrhythmias 2.39 1.45–3.95 0.001
Retrograde cardioplegia 0.33 0.19–0.59 0.001
Number of arterial bypass grafts 0.65 0.46–0.92 0.05
Peak CK-MB enzyme ratio
 5 ULN 1.00
 5 and  10 ULN 1.98 1.08–3.62 0.05
 10 and  20 ULN 2.11 1.01–4.42 0.05
 20 ULN 4.95 2.47–9.95 0.001
Abbreviations as in Tables 1 and 2.
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Figure 1. Comparison between therapy based on calcium channel blockers
(CCBs) and on conventional therapy. Note the decrease (p  0.013) in
nonfatal stroke and the increase in nonfatal myocardial infarction (MI)
(p  0.036). CV  cardiovascular.
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Table 2. Stroke: Calcium Channel Blocker Therapy Versus Conventional Therapy
of Hypertension
CCB (n/N) CT (n/N) RR 95% CI p Value Heterogeneity
Stroke, nonfatal
INSIGHT (ref. 3) 55/3,157 63/3,164 0.875 0.611–1.252 0.516
NORDIL (ref. 5) 138/5,410 174/5,471 0.802 0.644–1.000 0.051
STOP-2 (ref. 4) 161/2,196 186/2,213 0.872 0.712–1.068 0.198
Total, grade A 354/10,763 423/10,848 0.844 0.735–0.968 0.016 0.860
VHAS (ref. 12) 3/707 4/707 0.750 0.168–3.339 1.000
NICS-EH (ref. 11) 6/204 8/210 0.772 0.273–2.186 0.787
Total of above 363/11,674 435/11,765 0.842 0.735–0.964 0.013 0.987
Stroke, fatal
INSIGHT 12/3,157 11/3,164 1.093 0.483–2.474 0.838
NORDIL 21/5,410 22/5,471 0.965 0.531–1.753 1.000
STOP-2 46/2,196 51/2,213 0.909 0.613–1.348 0.682
Total, grade A 79/10,763 84/10,848 0.948 0.699–1.286 0.731 0.920
VHAS 2/707 0/707 * * 0.500
NICS-EH 2/204 0/210 * * 0.242
Total of above 83/11,674 84/11,765 0.996 0.737–1.346 0.979 0.360
Stroke, total
INSIGHT 67/3,157 74/3,164 0.907 0.654–1.258 0.610
NORDIL 159/5,410 196/5,471 0.820 0.668–1.008 0.059
STOP-2 207/2,196 237/2,213 0.880 0.737–1.050 0.161
Total, grade A 433/10,763 507/10,848 0.861 0.761–0.975 0.018 0.849
VHAS 5/707 4/707 1.250 0.337–4.636 1.000
NICS-EH 8/204 8/210 1.029 0.394–2.691 1.000
MIDAS (ref. 13) 6/442 3/441 1.995 0.502–7.929 0.506
Total grades A and B 452/12,116 522/12,206 0.873 0.773–0.986 0.029 0.808
*Statistics were not calculated for empty cells.
CI  confidence interval. Trial acronyms are defined in the references.
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